The U.S. administration is pushing for the onshoring of pharmaceutical production. But is there a sufficient supply of qualified people to staff expanded bioprocessing operations?

To explore that question, we sit down with Eric Langer, the president and managing partner of BioPlan Associates. For more than 20 years, his firm has been publishing the Annual Report of Biopharmaceutical Manufacturing Capacity and Production, so he has the data to back up his views.

We discussed:

• The current state of bioprocessing hiring and long-term trends

• The situation at CDMOs compared to innovator companies

• The impact of geopolitics, including changes to H-1B visa rules

• Job-seekers’ emotional reactions to the current climate

• The staff training gap for expanding manufacturing operations

Eric shares his assessment, putting it all into context—considering both current events and more than 20 years of data.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Eric Langer: LinkedIn

• Check out the 22nd Annual Report of Biopharmaceutical Manufacturing Capacity and Production

• Connect with our podcast host, Laura Bush: LinkedIn